GlassScriptPhysician profile
Kichiemon Asoma
NPI 1457548497
$5,695.55
in general payments reported to CMS, 2019-2025
19 companies · $2,018 in 2025
The $2,018 reported for 2025 was more than what 88% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $69.49 · 2020: $569 · 2021: $75.79 · 2022: $815 · 2023: $556 · 2024: $1,593 · 2025: $2,018.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,166.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,166.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sight Sciences, INC. | $1,910.18 | 2020-2025 | Omni Surgical System, Sion Surgical Instrument |
| Abbvie INC. | $961.20 | 2022-2025 | Lumigan, Alphagan P, Vuity |
| Tarsus Pharmaceuticals, INC. | $557.47 | 2024-2025 | Xdemvy |
| Bausch & Lomb Americas INC. | $547.97 | 2022-2025 | Miebo, Doctors Allergy Formula, Xiidra |
| Alcon Vision LLC | $455.01 | 2022-2025 | Rocklatan, Unity, Tryptyr |
| Oyster Point Pharma, INC. | $263.50 | 2022-2025 | Tyrvaya, Ryzumvi |
| Sun Pharmaceutical Industries INC. | $222.45 | 2019-2025 | Cequa |
| Harrow Eye, LLC | $165.88 | 2024-2025 | Vevye |
| Novartis Pharmaceuticals Corporation | $133.13 | 2019-2023 | |
| Allergan, INC. | $105.12 | 2019-2022 | |
| Rxsight INC | $97.91 | 2024 | Light Adjustable Lens (Lal), Rxsight Contact Lens, Rxsight Injector Cartridge |
| Kala Pharmaceuticals, INC. | $74.67 | 2021-2022 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $59.43 | 2020-2021 | |
| Amgen INC. | $37.33 | 2024-2025 | Tepezza |
| Dompe US, INC. | $28.88 | 2025 | Oxervate |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Thea Pharma INC. | $21.03 | 2023 | |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Eyevance Pharmaceuticals LLC | $19.01 | 2020 | |
| Astellas Pharma US INC | $15.98 | 2023 | Izervay |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kichiemon Asoma listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.